
Acutus Medical AFIB
Quarterly report 2024-Q3
added 11-14-2024
Acutus Medical Book Value 2011-2026 | AFIB
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Acutus Medical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -879 K | 75 M | 106 M | 127 M | -226 M | -132 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 127 M | -226 M | -8.53 M |
Quarterly Book Value Acutus Medical
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -10.3 M | -4.8 M | -4.02 M | -879 K | 31.7 M | 43.7 M | 60.5 M | 75 M | 57.8 M | 76.7 M | 68.8 M | 106 M | 134 M | 75.9 M | 100 M | 127 M | 127 M | 127 M | 127 M | 27.5 M | 27.5 M | 27.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 134 M | -10.3 M | 63.6 M |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Inogen
INGN
|
192 M | $ 6.32 | -2.02 % | $ 168 M | ||
|
IRadimed Corporation
IRMD
|
94.6 M | $ 99.89 | 0.69 % | $ 1.27 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | ||
|
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | ||
|
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M | ||
|
Aziyo Biologics
AZYO
|
27.7 M | - | 1.37 % | $ 20.5 M | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | ||
|
BioSig Technologies
BSGM
|
-1.42 M | - | 37.08 % | $ 85.7 M | ||
|
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | ||
|
IRIDEX Corporation
IRIX
|
9.52 M | $ 1.35 | -0.04 % | $ 21.8 M | ||
|
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | ||
|
LivaNova PLC
LIVN
|
1.2 B | $ 63.27 | 0.05 % | $ 3.45 B | ||
|
LENSAR
LNSR
|
18.6 M | $ 5.71 | -5.93 % | $ 65.8 M | ||
|
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | ||
|
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | ||
|
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | ||
|
AxoGen
AXGN
|
129 M | $ 32.42 | 2.11 % | $ 1.49 B | ||
|
CONMED Corporation
CNMD
|
1.03 B | $ 36.72 | 0.25 % | $ 1.14 B | ||
|
Medtronic PLC
MDT
|
48.3 B | $ 86.65 | -0.64 % | $ 111 B | ||
|
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B | ||
|
Electromed
ELMD
|
43.2 M | $ 24.67 | 0.73 % | $ 209 M | ||
|
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M | ||
|
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | ||
|
Cytosorbents Corporation
CTSO
|
11.1 M | $ 0.72 | 6.7 % | $ 39.2 M | ||
|
Aethlon Medical
AEMD
|
5.12 M | $ 2.15 | -6.52 % | $ 3.36 M | ||
|
BIOLASE
BIOL
|
1.96 M | - | -13.19 % | $ 166 K | ||
|
Orthofix Medical
OFIX
|
450 M | $ 11.77 | -0.84 % | $ 466 M | ||
|
AdaptHealth Corp.
AHCO
|
1.53 B | $ 11.48 | 10.66 % | $ 1.55 B | ||
|
Myomo
MYO
|
11.4 M | $ 0.69 | -2.17 % | $ 28.9 M | ||
|
Nano-X Imaging Ltd.
NNOX
|
189 M | $ 2.33 | -4.71 % | $ 137 M | ||
|
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | ||
|
EDAP TMS S.A.
EDAP
|
40.9 M | $ 3.85 | 3.08 % | $ 144 M | ||
|
OrthoPediatrics Corp.
KIDS
|
347 M | $ 15.84 | -3.83 % | $ 372 M | ||
|
Penumbra
PEN
|
1.43 B | $ 334.58 | -0.3 % | $ 13 B | ||
|
Outset Medical
OM
|
127 M | $ 3.49 | -3.6 % | $ 53.1 K | ||
|
Inspire Medical Systems
INSP
|
781 M | $ 51.53 | -1.3 % | $ 1.51 B | ||
|
Insulet Corporation
PODD
|
1.52 B | $ 225.21 | -0.82 % | $ 15.8 B | ||
|
Profound Medical Corp.
PROF
|
31.2 M | $ 5.1 | -5.56 % | $ 180 M | ||
|
Pulmonx Corporation
LUNG
|
54.1 M | $ 1.33 | -4.68 % | $ 54.1 M | ||
|
Quanterix Corporation
QTRX
|
296 M | $ 3.68 | -6.73 % | $ 157 M | ||
|
Cutera
CUTR
|
-172 M | - | -10.19 % | $ 1.99 M | ||
|
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | ||
|
InspireMD
NSPR
|
55.2 M | $ 1.8 | 4.05 % | $ 116 M | ||
|
Eargo
EAR
|
101 M | - | - | $ 10.2 M |